Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), filed a Form 4 on September 18, 2026, disclosing the exercise of a stock option and the sale of common stock on September 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Edward Carr exercised a stock option for 20,000 shares of common stock at an exercise price of $17.88 per share on September 17, 2026.
  • Shares sold: Carr disposed of all 20,000 acquired shares across five separate sale transactions on September 17, 2026, at weighted average prices ranging from $100.43 to $104.39.
  • Resulting ownership: Following all reported transactions, Carr directly held 0 shares of common stock.
  • Remaining options: Carr retained 43,818 stock options (right to buy) with an exercise price of $17.88, expiring January 23, 2034.
  • Trading plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Carr on June 18, 2026.
  • Vesting schedule: The underlying stock option vests in equal monthly installments over four years after January 1, 2024, subject to continued service.

Edward Carr's Option Exercise and Share Sales at Dianthus Therapeutics

According to the filing, Carr exercised a stock option covering 20,000 shares of Dianthus Therapeutics common stock at $17.88 per share on September 17, 2026, using transaction code "M." Immediately following the exercise, Carr held 20,000 shares directly. The filing notes the option was granted with shares vesting in equal monthly installments over the four years after January 1, 2024, subject to continued service to the issuer.

The filing further discloses that Carr disposed of all 20,000 shares through five separate sale transactions (transaction code "S") on the same date. The sales occurred at weighted average prices of $100.43 (7,928 shares), $101.37 (6,771 shares), $102.39 (3,501 shares), $103.20 (1,100 shares), and $104.39 (700 shares). Each weighted average price reflects multiple transactions within a stated price range, and according to the filing, Carr undertakes to provide full per-transaction detail to the issuer, any security holder, or SEC staff upon request.

After all reported transactions, the filing states that Carr's direct beneficial ownership of common stock stood at 0 shares. Carr continues to hold 43,818 stock options with an exercise price of $17.88 and an expiration date of January 23, 2034. The filing indicates all transactions were made pursuant to a Rule 10b5-1 trading plan Carr adopted on June 18, 2026. The Form 4 was signed by Adam Veness as attorney-in-fact for Edward Carr on September 18, 2026.

What Was Disclosed

The filing reports a stock option exercise of 20,000 shares at $17.88 and the subsequent sale of those shares at weighted average prices between $100.43 and $104.39, all conducted under a pre-established Rule 10b5-1 plan, leaving Carr with 0 directly held common shares.